Madrigal Pharmaceuticals, Inc.
MDGL
Market read
Madrigal Pharmaceuticals, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 4 directly disclosed connections are confirming.
- Increase in revenue driven by increased demand for Rezdiffra in the United States in 2026.
Invalidation: The isolated read changes if MDGL's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 4 directly disclosed connections are confirming.
No thresholded supportive filing evidence is available yet.
No thresholded adverse filing evidence is available yet.
- Increase in revenue driven by increased demand for Rezdiffra in the United States in 2026.
Price action
How the market is pricing the story
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 16 Sept, 13:35 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for MDGL. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for MDGL. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind MDGL
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
PFEPfizer Inc.partnerMay 6, 2026 ▾
“Key Developments In January 2026, we announced the expansion of our pipeline with an exclusive global license with Pfizer Inc.”
HTGCHercules Capital, Inc.lenderMay 6, 2026 ▾
“Credit Facilities Hercules Loan Facility In May 2022 we entered into a $250.0 million senior secured loan facility with Hercules Capital, Inc.”
Depended on by
ARWRArrowhead Pharmaceuticals, Inc.partnerMay 7, 2026 ▾
“Announced an exclusive worldwide license agreement with Madrigal Pharmaceuticals for ARO-PNPLA3, Arrowhead’s clinical stage RNA interference (RNAi) therapeutic designed to reduce liver expression of patatin-like phospholipase domain containing 3 (PNPLA3) as a…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 2 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
MDGL is currently a Leader in the organic co-movement group MASH Therapeutics. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for MDGL; it is not active in the latest market snapshot.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.